Clinical trial
Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are…
NCT00266318 · Beth Israel Medical Center, Other · Completed
Key facts
| NCT number | NCT00266318 |
|---|---|
| Title | Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy |
| Official title | A Phase 4 Open-Label Pilot Study of the Safety and Tolerability of High Dosage of CIFN Plus RBV Administered Daily for 48 Weeks in HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Pegylated Interferon Alfa Plus RBV Therapy |
| Lead sponsor | Beth Israel Medical Center, Other |
| Collaborators | InterMune Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis C |
| Intervention type | Drug |
| Interventions | Interferon Alfacon-1 and Ribavirin |
| Enrollment | 40 |
| Start date | Dec 1, 2005 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Dec 16, 2005 |
| Last update posted | Apr 17, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: